Tomeka Suber

Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.

Matthew A. Wiles, Nerissa C. Brown, Christopher M. Horvat, 2022, JAMA.

In vivo evolution of a Klebsiella pneumoniae capsule defect promotes complement-mediated opsono-phagocytosis and persistence during recurrent infection

Janet S. Lee, D. Stolz, D. Van Tyne, 2023, bioRxiv.